Boehringer Ingelheim Signs a Multi-Year Agreement with University of Texas for the Advancement of Cancer Therapies

 Boehringer Ingelheim Signs a Multi-Year Agreement with University of Texas for the Advancement of Cancer Therapies

Boehringer Ingelheim Signs a Multi-Year Agreement with University of Texas for the Advancement of Cancer Therapies

Shots:

  • The companies collaborated to establish a Virtual Research and Development Center, enabling data sharing and analysis and focusing on research of therapies for multiple types of cancers, including gastrointestinal and lung cancers
  • The focus of the agreement is to combine novel therapies from Boehringer’s oncology pipeline with patient-driven drug-development capabilities of MD Anderson’s Therapeutics Discovery division
  • The Virtual Research and Development Center will focus on researching therapies for cancer including KRAS inhibition concepts and TRAILR2 agonistic antibody for apoptosis

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Multivu

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post